Status:
COMPLETED
A Study of LUMIGAN® RC in the Clinical Setting
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Primary Open Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setti...
Eligibility Criteria
Inclusion
- Elevated IOP due to either primary open-angle glaucoma or ocular hypertension
- Determined by the treating physician to require treatment with LUMIGAN® RC
Exclusion
- None
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
1137 Patients enrolled
Trial Details
Trial ID
NCT01833741
Start Date
December 1 2009
End Date
March 1 2011
Last Update
September 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrie, Ontario, Canada